|Description||CYT387 sulfate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.|
This active molecular is a novel Janus Kinase 3 (JAK3) inhibitor. CP-690550A is an immunosuppressant for the treatment of rheumatoid arthritis, psoriasis, trans...
NS-018, a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tumor cells. It is still under Phase I/II ...
A cell-permeable pyridinylbutanone compound that inhibits cellular autophosphorylation of both the wild-type Jak2 and the constitutively active V167F mutant (IC...
Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rh...
ZM 39923 HCl
Selective inhibitor of Janus tyrosine kinase 3 (JAK3). pIC50 values are 7.1, 5.6, 4.4, and < 5.0 for JAK3, EGFR, JAK1 and CDK4 respectively. Breaks down in neut...
Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
Ruxolitinib sulfate (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1...
WP1066 is a Stat3 inhibitor and JAK2 inhibitor. WP1066 is also a novel analogue of the JAK2 inhibitor AG490, in JAK2 V617F-positive erythroleukemia HEL cells a...
CYT387 Mesylate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.
A cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (Janus family kinase 3; IC50 = 78 µM). Has no effect on JAK1, JAK2, or Zap...
SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...
TYK2-IN-2 is an inhibitor of TYK2 with potential for the treatment of inflammatory and autoimmune diseases.
Filgotinib, also known as GLPG0634, is a potent and selective JAK1 inhibitor. Filgotinib displayed a selectivity of 30-fold for JAK1- over JAK2-dependent signal...
Cyt387, also called Momelotinib, under the IUPAC name N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide, is an ATP competitive inhib...
Decernotinib, also known as VX-509 or VRT-831509 or adelatinib, is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex. VX-509 may repr...
Oclacitinib maleate was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).
AZD1480 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. AZD1480 inhibits JAK2 activation, leadin...
IC50 Value: JAK1 (5.9 nM) and JAK2 (5.7 nM). Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nan...
Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic acti...
Peficitinib, also known as ASP015K and JNJ-54781532, is a novel potent JAK inhibitor, which demonstrated potent efficacy in adjuvant-induced arthritis model in ...